News
TPST
3.480
+1.16%
0.040
Weekly Report: what happened at TPST last week (0415-0419)?
Weekly Report · 4d ago
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch
Seeking Alpha · 04/17 17:26
BUZZ-U.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
The Nasdaq and the S&P 500 were muted on Tuesday as higher Treasury yields pressured equities. The blue-chip Dow bucked the trend on robust results from health insurance heavyweight UnitedHealth. The Dow Jones Industrial Average was up 0.13% at 37,783.35. UnitedHealth Group's quarterly results beat expectations.
Reuters · 04/16 17:52
BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals
Dow Jones Industrial Average up 0.13% after upbeat results from health insurer UnitedHealth. Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals among top stocks on the move. Higher Treasury yields and conflict in the Middle East keep investors on edge.
Reuters · 04/16 15:39
BUZZ-U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene
The Dow Jones Industrial Average was down 0.45% on Monday. Goldman Sachs boosted by robust gains. Snap One, Encore Wire, Centene were among the top stocks on the NYSE. The S&P 500 and Nasdaq Composite both fell on the day. U.S. Retail sales were stronger than expected.
Reuters · 04/15 17:48
BUZZ-U.S. STOCKS ON THE MOVE-Cisco Systems, Inspired Entertainment, Spirit Airlines
Dow Jones Industrial Average was up 0.36% at 38,119.77. Goldman Sachs boosted by robust gains. Top three S&P 500 percentage gainers: M&T Bank, Centene, Snap One. Apple down 0.6% after falling in premarket trading.
Reuters · 04/15 16:13
Weekly Report: what happened at TPST last week (0408-0412)?
Weekly Report · 04/15 11:38
Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments
TipRanks · 04/09 15:25
Weekly Report: what happened at TPST last week (0401-0405)?
Weekly Report · 04/08 11:44
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Byrna Technologies shares jumped 7.1% to $14.74 on Friday. The company reported better-than-expected first-quarter revenue and announced a CFO transition. MediaCo Holding Inc. Shares jumped 141.7% in today's mid-day session.
Benzinga · 04/05 17:06
Tempest Announces Publication Of Data From Phase 1 Trial Of TPST-1120 In Patients With Advanced Solid Tumors In Journal Of Cancer Research Communications
TPST-1120, a first-in-class, oral, selective PPAR antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancers. Based on subsequent positive randomized data, Company preparing to move TPST- 1120 into pivotal Phase 3 trial in HCC.
Benzinga · 04/04 12:10
TEMPEST THERAPEUTICS INC: TPST-1120 WAS WELL TOLERATED BOTH AS MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB
Reuters · 04/04 12:00
Weekly Report: what happened at TPST last week (0325-0329)?
Weekly Report · 04/01 11:40
Weekly Report: what happened at TPST last week (0318-0322)?
Weekly Report · 03/25 11:44
Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles
TipRanks · 03/21 06:01
Tempest Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Tempest Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 38 cents per share. The mean expectation of five analysts was for a loss of 39 cents. Reported revenue was zero; analysts expected zero; shares had fallen 15.0% this quarter.
Reuters · 03/20 12:00
Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)
TipRanks · 03/20 11:16
Tempest Therapeutics (TPST) Receives a Buy from Scotiabank
TipRanks · 03/20 11:16
Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
Dow Jones · 03/20 10:49
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Benzinga · 03/20 10:39
More
Webull provides a variety of real-time TPST stock news. You can receive the latest news about Tempest Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.